Cladribine is a nucleoside analogue widely used in the pharmaceutical industry for the treatment of several neoplasms, including hairy-cell leukemia among others. This compound has also shown efficacy in the treatment of autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. In this work, a green bioprocess for cladribine biosynthesis using immobilized Arthrobacter oxydans was developed. The microorganism was stabilized by entrapment immobilization in the natural matrix alginate. Different reaction parameters were optimized obtaining a biocatalyst able to achieve cladribine bioconversion values close to 85% after 1 hr, the shortest reaction times reported so far. The developed bioprocess was successfully scaled-up reaching a productivity of 138 mg L hr . Also, the biocatalyst was stable for 5 months in storage and in 96 hr at operational conditions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/btpr.2927 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Analysis of nitrogen metabolism-related gene expression in hepatocellular carcinoma to establish relevant indicators for prediction of prognosis and guidance of immunotherapy.
Comput Methods Biomech Biomed Engin
December 2024
Department of Hepatobiliary Surgery, Quzhou Hospital Affiliated of Wenzhou Medical University (Quzhou People's Hospital), Quzhou, Zhejiang, China.
Background: The prognosis of cancers is strongly connected with nitrogen metabolism (NM), which plays a critical role in the microenvironment and growth of tumors. It is unsubstantiated, however, how important NM-related genes are for the prognosis of hepatocellular carcinoma (HCC).
Methods: Using publicly available data, we examined potential mechanisms of NM-related genes in HCC, created a predictive model, and assessed immune infiltration and medication sensitivity.
Effects of cladribine on intrathecal and peripheral B and plasma cells.
Clin Exp Immunol
January 2025
Clinical Board Medicine (Neuroscience), The Royal London Hospital, Barts Health NHS Trust, London, UK.
Introduction: Cladribine is a deoxyadenosine analogue that can penetrate the blood-brain barrier. It is used to treat multiple sclerosis (MS). However, the mechanistic understanding of the effect of this highly effective therapy on B cells and plasma cells in the central nervous system compartment is limited.
View Article and Find Full Text PDFElectrochemical quantification based on the interactions of nucleoside analog cladribine with dsDNA via experimental and in-silico studies.
Int J Biol Macromol
January 2025
Department of Chemistry, Faculty of Science and Letters, Istanbul Technical University, Maslak, Istanbul 34469, Türkiye. Electronic address:
Cladribine is a deoxyadenosine analog prodrug originally developed to treat hairy-cell leukemia and other lymphoproliferative diseases. However, it is now primarily used in the treatment of relapsing types of multiple sclerosis (MS). Understanding how medications interact with dsDNA is crucial for developing more effective and efficient medications.
View Article and Find Full Text PDFHairy cell leukemia (HCL) and HCL-like disorders: present, emergent treatment options and future directions.
Expert Rev Hematol
December 2024
CHU Caen Normandie, Avenue Côte de Nacre, Hématologie, Caen cedex, France.
Article Synopsis
- * Differentiating HCL from similar disorders is crucial, as recent advancements in molecular biology and new drug developments (like BRAF and MEK inhibitors) show promise for relapsed cases, alongside ongoing clinical trials.
- * For treating fit patients with HCL or its variant, the combination of Cladribine and rituximab is standard, while BRAF and BTK inhibitors are considered for patients with relapsed conditions; optimal treatment strategies are still being explored. *
De-escalation from anti-CD20 to cladribine tablets in multiple sclerosis: A pilot study.
Mult Scler Relat Disord
December 2024
Multiple Sclerosis Center (MSC), Department of Neurology, Neurocenter of Southern Switzerland, Lugano 6900, Switzerland; Faculty of biomedical Sciences, Università della Svizzera Italiana, Via Buffi 13, 6900 Lugano, Switzerland. Electronic address:
Prolonged treatment with anti-CD20 antibodies can lead to hypogammaglobulinemia and increased infection risk in multiple sclerosis (MS). We investigated switch from anti-CD20 to cladribine as a strategy to prevent immunoglobulin reduction while preserving efficacy. We prospectively analysed serum IgG, IgM, neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in 44 patients, 14 who were switched from anti-CD20 to cladribine and 30 continuing anti-CD20.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!